Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Last year, Biogen announced plans to cut 1,000 jobs — over 11% of its workforce — and reduce operating expenses by an additional $700 million by 2025. On Wednesday, the company projected that ...